Baylor College of Medicine

Norihiro Watanabe

Malcolm K Brenner

Amanda Rosewell Shaw

Caroline Elaine Porter

Masataka Suzuki

Cliona M Rooney

Ann Marie Leen

Juan Fernando Vera Valdes

Juan Fernando Valdes

The present disclosure concerns combination therapy for cancer that utilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor; and (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen. In particular embodiments, the virus comprises nucleic acid encoding an immunomodulatory factor comprises nucleic acid encoding IL-12 and/or antagonist anti-PD-L1 antibody.

Oncolytic virotherapy with helper-dependent adenoviral-based vectors expressing immunomodulatory molecules

The present disclosure concerns combination therapy for cancer that utilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor, and (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen. In particular embodiments, the virus comprises nucleic acid encoding an immunomodulatory factor comprises nucleic acid encoding IL-12 and/or antagonist anti-PD-L1 antibody.

Oncolytic virotherapy and immunotherapy

Embodiments of the disclosure concern cell therapy methods and compositions utilizing cells expressing at least a chimeric TGF&#x3b2; receptor including the exodomain of a TGF&#x3b2;II receptor and an endodomain that is not from TGF&#x3b2; receptor, thereby converting the negative signal of TGF&#x3b2; for T cell proliferation into a T cell activation signal. In at least certain aspects, cells harboring the chimeric TGF&#x3b2; receptor also harbor one or more chimeric antigen receptors.

Immunosuppressive TGF-&#x3b2; signal converter

Growing community of inventors

Houston, TX, United States of America

Norihiro Watanabe